XORTX Therapeutics Files Q1 2025 Financial Report
Ticker: XRTX · Form: 6-K · Filed: May 16, 2025 · CIK: 1729214
Sentiment: neutral
Topics: financial-report, quarterly-results, biotech
TL;DR
XORTX dropped Q1 2025 financials, check 'em out.
AI Summary
XORTX Therapeutics Inc. filed a Form 6-K on May 16, 2025, reporting its financial results for the three months ended March 31, 2025. The filing includes condensed interim consolidated financial statements and Management Discussion and Analysis. The company is incorporated in Alberta, Canada, and its principal executive offices are located in Vancouver.
Why It Matters
This filing provides investors with an update on XORTX Therapeutics' financial performance and operational status for the first quarter of 2025, crucial for assessing the company's health and future prospects.
Risk Assessment
Risk Level: medium — As a clinical-stage biotechnology company, XORTX faces inherent risks related to drug development, regulatory approvals, and market adoption.
Key Numbers
- Q1 2025 — Reporting Period (Financial results for the three months ended March 31, 2025.)
Key Players & Entities
- XORTX Therapeutics Inc. (company) — Registrant
- Allen Davidoff (person) — Chief Executive Officer
- March 31, 2025 (date) — End of reporting period
- May 16, 2025 (date) — Filing date
FAQ
What specific financial details are included in the Condensed Interim Consolidated Financial Statements for the three months ended March 31, 2025?
The filing indicates that Exhibit 99.1 contains the Condensed Interim Consolidated Financial Statements for the three months ended March 31, 2025, but the specific details are not provided in the summary text.
What is the primary purpose of the Management Discussion and Analysis (MD&A) filed as Exhibit 99.2?
The MD&A for the three months ended March 31, 2025, is intended to provide management's perspective on the company's financial condition and results of operations.
Who signed the Form 6-K on behalf of XORTX Therapeutics Inc.?
The Form 6-K was signed by Allen Davidoff, Chief Executive Officer, on May 15, 2025.
What is XORTX Therapeutics Inc.'s Standard Industrial Classification (SIC) code?
XORTX Therapeutics Inc.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Where are XORTX Therapeutics Inc.'s principal executive offices located?
XORTX Therapeutics Inc.'s principal executive offices are located at Suite 2400 - 745 Thurlow Street, Vancouver, A1, V6E 0C5.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 16, 2025 by Allen Davidoff regarding XORTX Therapeutics Inc. (XRTX).